Proteomics in cancer screening and management in gynecologic cancer

Current Oncology Reports

Volumn 6, Issue 6, 2004, Pages 456-462

  Hu, Wei ^a   Wu, Weiguo ^a   Kobayashi, Ryuji ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CELL PROTEIN; CYTOKERATIN 19; FK 506 BINDING PROTEIN; GLYCOPROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HEAT SHOCK PROTEIN 70; LYSOPHOSPHATIDIC ACID; MANUMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; QUERCETIN; RHO FACTOR; TUMOR ANTIGEN;

ANALYTIC METHOD; BIOINFORMATICS; BLOOD ANALYSIS; CANCER SCREENING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG MECHANISM; EARLY DIAGNOSIS; GENE FUNCTION; GENETIC DATABASE; GYNECOLOGIC CANCER; HIGH THROUGHPUT SCREENING; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MONITORING; ONCOLOGY; OVARY CANCER; POPULATION RESEARCH; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN PURIFICATION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS;

EID: 9744283522     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0076-4     Document Type: Review

References (51)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 541:8-29.
2. Diamandis EP: Tumor markers: past, present, and future. In Tumor Markers. Edited by Diamandis EP, Lilja A, Chan D, et al. Washington, DC: American Association for Clinical Chemistry; 2002:3-8.
3. Bast RC Jr, Xu FJ, Yu YH, et al.: CA 125: the past and the future. Int J Biol Markers 1998, 134:179-187.
4. Bandera CA, Ye B, Mok SC: New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 2003, 151:51-55.
5. Mills GB, Bast RC Jr, Srivastava S: Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 2001, 9319:1437-1439.
6. Petricoin EF, Zoon KC, Kohn EC, et al.: Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002, 19:683-695.
7. Hanash S: Disease proteomics. Nature 2003, 422:226-232.
8. Krieg RC, Paweletz CP, Liotta LA, et al.: Clinical proteomics for cancer biomarker discovery and therapeutic targeting. Technol Cancer Res Treat 2002, 14:263-272.
9. Wilkins MR, Sanchez JC, Gooley AA, et al.: Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1996, 13:19-50.
10. Wu W, Hu W, Kavanagh JJ: Proteomics in cancer research. Int J Gynecol Cancer 2002, 125:409-423.
11. Anderson L, Anderson NG: High resolution two-dimensional electrophoresis of human plasma proteins. Proc Natl Acad Sci U S A 1977, 7412:5421-5425.
12. Adkins JN, Varnum SM, Auberry KJ, et al.: Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002, 112:947-955.
13. Pieper R, Su Q, Gatlin CL, et al.: Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003, 34:422-432.
14. Zhu H, Snyder M: Protein chip technology. Curr Opin Chem Biol 2003, 71:55-63.
15. Service RF: Proteomics: searching for recipes for protein chips. Science 2001, 294:2080-2082.
16. Yates JR III. Mass spectrometry, from genomics to proteomics. Trends Genet 2000, 161:5-8.
17. Yates JR III, Carmack E, Hays L, et al.: Automated protein identification using microcolumn liquid chromatography-tandem mass spectrometry. Methods Mol Biol 1999, 112:553-569.
18. Yates JR III, McCormack AL, Schieltz D, et al.: Direct analysis of protein mixtures by tandem mass spectrometry. J Protein Chem 1997, 165:495-497.
19. Dongre AR, Eng JK, Yates JR III: Emerging tandem-mass-spectrometry techniques for the rapid identification of proteins. Trends Biotechnol 1997, 1510:418-425.
20. Wulfkuhle JD, McLean KC, Paweletz CP, et al.: New approaches to proteomic analysis of breast cancer. Proteomics 2001, 110:1205-1215.
21. Issaq HJ, Veenstra. TD, Conrads TP, et al.: The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002, 2923: 87-592.
22. Ciphergen. http://www.ciphergen.org Accessed June 12, 2004.
23. McGuffin LJ, Bryson K, Jones DT: The PSIPRED protein structure prediction server. Bioinformatics 2000, 164: 04-405.
24. Xu Y, Shen Z, Wiper DW, et al.: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998, 2808:719-723.
25. Hogdall EV, Hogdall CK, Kjaer SK, et al.: OVX1 radioimmuno-assay results are dependent on the method of sample collection and storage. Clin Chem 1999, 455:692-694.
26. Engelen MJ, de Bruijn HW, Hollema H, et al.: Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol 2000, 781:16-20.
27. Klockars M, Pettersson T, Froseth B, et al.: Concentration of tumor-associated trypsin inhibitor (TATI) in pleural effusions. Chest 1990, 985:1159-1164.
28. Mok SC, Chao J, Skates S, et al.: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001, 9319: 458-1464.
29. Mazurek A, Niklinski J, Laudanski T, et al.: Clinical tumour markers in ovarian cancer. Eur J Cancer Prev 1998, 71:23-35.
30. Bast RC Jr, Urban N, Shridhar V, et al.: Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002, 107:61-97.
31. Petricoin EF, Ardekani AM, Hitt BA, et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-527.
32. Petricoin EF III, Ornstein DK, Paweletz CP, et al.: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002, 9420:1576-1578.
33. Paweletz CP, Trock B, Pennanen M, et al.: Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001, 174:301-307.
34. Petricoin EE, Paweletz CP, Liotta LA: Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia 2002, 74:433-440.
35. Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004, 965:353-356.
36. Diamandis EP: Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003, 498:1272-1275.
37. Conrads TP, Fusaro VA, Ross S, et al.: High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004, 112:163-178.
38. Ye B, Cramer DW, Skates SJ, et al.: Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003, 98:2904-2911.
39. Ahmed N, Barker G, Oliva KT, et al.: Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 2004, 91:129-140.
40. Ott HW, Lindner H, Sarg B, et al.: Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 2003, 6321:7507-7514.
41. Jones MB, Krutzsch H, Shu H, et al.: Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002, 21:76-84.
42. Hu W, Wu W, Verschraegen CF, et al.: Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics 2003, 310:1904-1911.
43. Young TW, Mei FC, Yang G, et al.: Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 2004, 6413:4577-4584.
44. Wulfkuhle JD, Aquino JA, Calvert VS, et al.: Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003, 311: 085-2090.
45. Markman M: Limitations to the use of the CA-125 antigen level in ovarian cancer. Curr Oncol Rep 2003, 54:263-264.
46. Jacobs IJ, Skates SJ, MacDonald N, et al.: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999, 353:1207-1210.
47. Bast R, Woolas R: Screening for ovarian cancer: multiple markers may outperform CA 125 alone. BMJ 1993, 306: 684-1685.
48. Bast RC: Perspectives on the future of cancer markers. Clin Chem 1993, 3911:2444-2451.
49. Markman M: The role of CA-125 in the management of ovarian cancer. Oncologist 1997, 21:6-9.
50. Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 111:845-867.
51. Issaq HJ: The role of separation science in proteomics research. Electrophoresis 2001, 2217:3629-3638.